HRSA-22-084: National Fetal, Infant, and Child Death Review Center
Closed
This grant is closed. A newer notice from the same program is open now: Women's Initiative for Screening and Health (WISH) (HRSA-27-072). Status: Closes January 8, 2027 (62 days left). It is in our archive of Health Resources and Services Administration notices from 2021.
Health Resources and Services Administration offered grants of up to $2.4 million to the applicants described in the notice. It expected to make one award worth $2.4 million in total. Applications closed on February 16, 2022.
From the official notice on Grants.gov, last changed November 18, 2021. Checked November 7, 2026.
- Award ceiling$2.4 million
- Total funding$2.4 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | November 18, 2021 |
|---|---|
| Deadline | February 16, 2022 |
| Archived by Grants.gov | April 17, 2022 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Any domestic public or private entity, including an Indian tribe or tribal organization (as those terms are defined at 25 U.S.C. 450b), is eligible to apply for this federal funding. See Title 42 CFR § 51a.3(a). Domestic faith-based and community-based organizations are also eligible to apply for funding.
Is this a realistic fit?
- Past Special Projects of Regional and National Significance awards averaged $1.6 million; this notice allows up to $2.4 million per award.
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the National Fetal, Infant, and Child Death Review Center (FICDR) program, which aims to increase the capacity of community and state Child Death Review (CDR) and Fetal Infant Mortality Review (FIMR) teams to collect high-quality uniform data, translate data into action at the community, state, and national levels, and expand fetal, infant, and child death reviews to additional states, territories and tribes. This program will support coordinated leadership and technical assistance to state and community fetal, infant, and child fatality review teams on the fatality review processes to ensure a standardized and coordinated approach for quality data collection, team reviews, and dissemination of findings to inform practice and prevention strategies. Findings from these reviews will help HRSA, States, and communities better understand the circumstances preceding fetal, infant, child, and adolescent deaths in our nation and can lead to improved systems of care and service delivery as well as targeted policies or legislation that impact the maternal and child health (MCH) population. The goals of the FICDR Program are to support a National Center to: • Provide coordinated leadership, and cohesive guidance, training, and technical assistance to state, community, and tribal CDR and FIMR teams, including those that are Healthy Start grant recipients. • Support a CDR and FIMR national Case Reporting System including standardized data collection and quality improvement efforts. • Disseminate data and key findings from CDR and FIMR teams to inform prevention efforts, including innovative, user-friendly data visualization tools and data summaries. • Facilitate the translation of CDR and FIMR data and recommendations into practice, system, and policy change at the community, state, and national levels.
Who has won Special Projects of Regional and National Significance grants before
From fiscal 2021 to 2025, Special Projects of Regional and National Significance (93.110) awarded $1.4 billion across 842 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Zero to Three National Center for Infants, Toddlers & Families | District of Columbia | 2 | $54.3 million |
| University Hospitals Cleveland Medical Center | Ohio | 1 | $51.5 million |
| Children's National Medical Center | District of Columbia | 1 | $37.2 million |
| University of North Carolina at Chapel Hill | North Carolina | 8 | $29.1 million |
| American Academy of Pediatrics | Illinois | 8 | $26.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-072, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-22-084 still open?
No. It closed on February 16, 2022. A newer notice is open: HRSA-27-072, closes January 8, 2027 (62 days left).
Who can apply for National Fetal, Infant, and Child Death Review Center?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for National Fetal, Infant, and Child Death Review Center?
Closed February 16, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $2.4 million each. About $2.4 million in total for one award.
Who has won Special Projects of Regional and National Significance grants before?
The largest recipients over five fiscal years were Zero to Three National Center for Infants, Toddlers & Families, University Hospitals Cleveland Medical Center, Children's National Medical Center. The program made 842 awards worth $1.4 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)